The trajectory of Sildenafil presents a nuanced case for stakeholders in the medicinal sector. While initially a tremendous success, creating billions, the intellectual property end and the subsequent flood of generic alternatives have significantly changed earnings. This raises questions about the long-term viability of related therapeutic innovat